Navigation Links
Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227/ ITMN-191 in Patients With Chronic Hepatitis C
Date:8/19/2009

treatment for a total of 48 weeks.

About RG7227/ ITMN-191

RG7227/ ITMN-191 is a potent, macrocyclic inhibitor of HCV NS3/4A protease activity, and has produced multi-log10 reductions in HCV levels in chronic HCV patients, when administered for 14 days as monotherapy. When RG7227/ ITMN-191 is combined with PEGASYS and COPEGUS, or the NS5B polymerase inhibitor RG7128, it reduced viral loads below the limit of detection in a majority of study-treated patients. RG7227/ ITMN-191 was safe and well tolerated in these studies.

About PEGASYS

PEGASYS, in combination with COPEGUS (ribavirin), is indicated for the treatment of adults with chronic HCV who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that are clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy). In addition, PEGASYS in combination with COPEGUS is the first and only FDA-approved regimen for the treatment of chronic HCV in patients coinfected with HCV and HIV. PEGASYS is the only pegylated interferon indicated for the treatment of adult patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation).

PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is administered orally two times a day as a split dose. Roche has backed PEGASYS with the most extensive clinical research program ever undertaken in HCV, with major studies initiated to advance treatment for HCV patients with unmet needs, including patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and p
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Rochester Medical Reports Third Quarter Results
2. Roche Cardiac 200 Offers Rapid Cardiac Diagnostics for the Point of Care
3. Rochester Medical Announces Third Quarter 2009 Earnings Conference Call July 30, 2009
4. Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc.
5. Roche Diabetes Care Announces Unique Coaching Program for Diabetes Educators as Part of Long-Term Commitment to Fight the Disease
6. NJLRA Statement in Response to Roches Discontinuation of Accutane(R)
7. Orochem Technologies Acquires Oligonet, a Custom Oligo Synthesis Business
8. Purple Communications Dream Bigger Initiative Honors Rochester Physician and Deaf Community Trailblazer
9. Rochester Medical Corporation Set to Join Russell 3000 Index
10. Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
11. Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 20, 2014 Consistent premium price ... the Vision Insurance industry in recent years; however, ... of industry margins. From 2009 to 2014, industry ... provide coverage for routine eye exams and other ... contact lens and refractive surgery. According to IBISWorld ...
(Date:9/19/2014)... Unbound , an international humanitarian organization based ... the Philippines being affected by both a tropical storm and ... to the nearest public schools while others moved to higher ... winds to portions of the northern Philippines. , The ... with more than 10 feet of water. , “It ...
(Date:9/19/2014)... On September 16, Camino Public Relations was ... Top Places to Work in PR Awards Luncheon at ... honorable mentions in two categories for “Multicultural Campaign” and ... Latina voices in the media. , "We're honored to ... of its efforts to improve the national conversation about ...
(Date:9/19/2014)... NH 9/18/14) A leading Dartmouth researcher, working with The ... a paper published today in the Journal of ... increase the risk of melanoma. , "For the first ... length of these telomeres play a part in the ... study Mark Iles, PhD, School of Medicine at the ...
(Date:9/19/2014)... York, New York (PRWEB) September 19, 2014 ... in a transvaginal mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) ... state court next month, Bernstein Liebhard LLP reports. ... in Dallas District Court, the company asserts that claims ... the Texas Civil Practice and Remedies Code, a section ...
Breaking Medicine News(10 mins):Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Melanoma risk found to have genetic determinant 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4
... will be a great relief to the parents of Canada’s ... the story, doctors have confirmed //after days of several tests ... twins, known by the names Krista and Tatiana Hogan came ... are four months of age, portray distinct sleep patterns, vision, ...
... and type 2 diabetes increases the risk of death for ... of heart disease deaths by itself, but together they’ve been ... an analysis of more than 900 patients with established coronary ... with both type 2 diabetes and symptoms of depression were ...
... of investigators, by defying the norm. A key enzyme, ... disease, is absent in this strain of gonorrhea. The ... strain, making detection of gonorrhea extremely difficult. ... this odd strain of gonorrhea, was perceived to be ...
... Delhi will continue as a model state in the war ... million kids// below the age of five will be immunized ... Dikshit administered anti-polio drops to a number of children at ... of polio in 2006, an increase from just one case ...
... prevent amputation and restore blood flow in the lower ... gangrene (tissue loss). At eighteen months, the tiny arteries ... success rate, thus preventing amputation. This success rate was ... a six-year period of time. The blockages were caused ...
... no escape into outdoor areas in eateries or distant patios, as ... public. ,The new anti smoking legislation introduced a few ... well as in public doorways, and 'near' the doors, windows and ... , Says Health Minister George Abbott: 'Some people will see it ...
Cached Medicine News:Health News:Combination of Depression and Type-2-diabetes Lethal for Heart Patients 2Health News:Multi-Year Data Shows PAD Treatment Prevents Amputation 2
(Date:9/19/2014)... 19, 2014 According to ... (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), ... technologies - Global Forecast to 2019" published by ... reach $19,786.3 Million by 2019 from $14,240.0 Million ... 2014 to 2019. Browse 74 market ...
(Date:9/19/2014)... Research and Markets has announced the addition of ... Mental Disorder) Market - Forecast to 2023" report to ... the human microbiome market is segmented by application, disease, product, ... to be valued as $294 million in 2019 and is ... forecast period of 2019-2023. The market is driven by growing ...
(Date:9/19/2014)... FLINT, Mich. , Sept. 19, 2014  Diplomat, ... appointment of David Dreyer to the Board ... an independent director and will also serve as chair ... has almost 30 years of accounting, financial, compliance and ... 2010, Mr. Dreyer has served as chief financial officer, ...
Breaking Medicine Technology:Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3David Dreyer Appointed to Diplomat Board of Directors 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: